Literature DB >> 27486825

Prevalence of Psychoactive Substance Consumption in People With Obesity.

Hélène Donnadieu-Rigole1,2,3, Laetitia Olive1, Bertrand Nalpas4,5, Yohan Duny6, David Nocca2,7, Pascal Perney2,5.   

Abstract

OBJECTIVE: The aim of this study was to evaluate the prevalence and the kind of psychoactive substances consumed by people with obesity.
METHODS: Patients were included at their first visit for bariatric surgery. Socio-demographic characteristics, anxiety, depressive disorders and psychoactive substance consumption were assessed. The prevalence of psychoactive substance consumption was compared to that of the general population reported by the French National Institute of Prevention and Health Education.
RESULTS: One hundred (100) patients were consecutively recruited: 60 women (mean age 41 ± 14 years) and 40 men (mean age 46 ± 13 years). Sixty-seven percent of subjects consumed alcohol. Consumption rates of cannabis (21% vs. 10%), cocaine (7.0% vs. 0.8%) and amphetamine (6.0% vs. 0.3%) were significantly (p < .0001) higher in people with obesity than in the general population.
CONCLUSIONS: People with obesity have an excess risk of amphetamine, cocaine and cannabis consumption. This consumption may increase the risk of cardiovascular and psychiatric morbidity and should therefore be detected before surgery.

Entities:  

Keywords:  People with obesity; consumption; prevalence; psychoactive substances

Mesh:

Substances:

Year:  2016        PMID: 27486825     DOI: 10.1080/10826084.2016.1191514

Source DB:  PubMed          Journal:  Subst Use Misuse        ISSN: 1082-6084            Impact factor:   2.164


  1 in total

1.  Psychiatric Burden in the Morbidly Obese in Multidisciplinary Bariatric Clinic in South India.

Authors:  Stephen Amarjeet Jiwanmall; Dheeraj Kattula; Munaf Babajan Nandyal; Shanmugasundaram Devika; Nitin Kapoor; Mini Joseph; Sandhiya Paravathareddy; Sahana Shetty; Thomas V Paul; Simon Rajaratnam; Nihal Thomas; Vijay Abraham; Inian Samarasam
Journal:  Indian J Psychol Med       Date:  2018 Mar-Apr
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.